ProPhase Labs, Inc. Cash
ProPhase Labs, Inc. (PRPH) had Cash of $1.40 million as of 2022-02-28, per its 10-K filed 2025-04-01.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2025-04-01
- 2022-02-28: Cash $1.40M; Cash as first filed $1.44M.
- 2021-09-30: Cash $8.70M.
- 2021-06-30: Cash $17.90M.
- 2021-03-31: Cash $32.70M.
| Period end | Cash | Cash as first filed |
|---|---|---|
| 2022-02-28 | $1.40M 10-K · filed 2025-04-01 | $1.44M 10-Q · filed 2022-05-13 |
| 2021-09-30 | $8.70M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $17.90M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $32.70M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $7.40M 10-K · filed 2021-03-31 | |
| 2020-09-30 | $10.90M 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $2.60M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $800.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $500.00K 10-K · filed 2020-03-26 | |
| 2019-09-30 | $1.10M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.20M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $2.60M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $1.60M 10-K · filed 2019-03-26 | |
| 2018-09-30 | $2.40M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $3.80M 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $3.60M 10-Q/A · filed 2018-08-20 | |
| 2017-12-31 | $3.30M 10-K/A · filed 2018-08-20 | |
| 2017-09-30 | $3.90M 10-Q/A · filed 2018-08-20 | |
| 2017-06-30 | $37.30M 10-Q/A · filed 2018-08-20 | |
| 2017-03-31 | $42.80M 10-Q/A · filed 2018-08-20 | |
| 2016-12-31 | $441.00K 10-K · filed 2017-02-24 | |
| 2016-09-30 | $375.00K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $1.10M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $2.50M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $1.70M 10-K · filed 2016-03-29 | |
| 2015-09-30 | $1.30M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $3.80M 10-Q · filed 2015-08-12 | |
| 2012-09-30 | $1.80M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $4.60M 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |